Advances in Targeted Therapies for Non-Small Cell Lung Cancer at the 2017 American Society of Clinical Oncology Annual Meeting

primelines-nsclc-asco-updates-2017-prime-oncology

Alectinib, the optimal first-line therapy for ALK-positive NSCLC. In the global, randomized phase III ALEX study (Abstract LBA9008) involving 303 previously untreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC), the anaplastic lymphoma kinase (ALK) inhibitor alectinib (600 mg twice daily) compared with crizotinib (250 mg twice daily) reduced the risk of progression or… » Read More

Read More

Abiraterone Plus Androgen Deprivation Therapy: A New Standard of Care for Hormone-Sensitive Metastatic Prostate Cancer

prIMEline-abiraterone-benefit-in-prostate-cancer

Two large trials (LATITUDE and STAMPEDE), presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that  upfront treatment with abiraterone plus prednisone and androgen deprivation therapy (ADT) in hormone-sensitive metastatic prostate cancer improves overall survival compared to ADT alone. These results will likely led to immediate practice change.   According to… » Read More

Read More

Emerging Data in Gastrointestinal Cancers from the American Society of Clinical Oncology (ASCO) Annual Meeting

primelines June GI updates ASCO 2017

• Using risk-based approach to personalize adjuvant chemotherapy duration for stage III colon cancer. According to a prospective pooled analysis of six phase III adjuvant colon cancer clinical trials with 12,800 patients, a 3-month course of adjuvant combination chemotherapy of oxaliplatin and intravenous 5-fluorouracil (FOLFOX) or oxaliplatin and oral capecitabine (CAPOX) has similar efficacy and… » Read More

Read More

New Phase III Trials Results on Targeted Therapy in Breast Cancer From the ASCO Annual Meeting

asco breast cancer prime oncology

The American Society of Clinical Oncology (ASCO) Annual Meeting was held this past week in Chicago and below we have summarized some of the eagerly awaited results of phase III clinical trials in breast cancer. Olaparib Superior to Chemotherapy in BRCA-Associated Metastatic Breast Cancer According to results from the phase III OlympiAD trial presented by… » Read More

Read More

Four New Indications Approved for Pembrolizumab in May

Pembrolizumab FDA approvals

In May, the US Food and Drug Administration (FDA) granted four new indications to the programmed death receptor-1 (PD-1) inhibitor pembrolizumab (Keytruda®, Merck). These new indications included first-line treatment of nonsquamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, second-line treatment of advanced urothelial cancer, first-line treatment of urothelial cancer in cisplatin-ineligible patients, and… » Read More

Read More

What’s Trending at the ASCO Annual Meeting This Year

annual-meeting-preview-prime-oncology

The American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held at the McCormick Place Convention Center in Chicago from June 2-6, is fast approaching. According to the organizer, more than 38,000 participants from around the globe are expected to discuss the latest clinical trials updates and new research findings in oncology, state-of-the-art… » Read More

Read More

Hyperprogression Observed During Anti-PD-1/PD-L1 Therapy in Some Patients With Advanced Head and Neck Cancer

Increased cancer cell growth

Inhibitors of programmed death receptor 1 (PD-1) are associated with significant improvements in overall survival (OS) and durable responses in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). However, a retrospective analysis from four French centers found that approximately one third of patients with recurrent and/or metastatic SCCHN treated… » Read More

Read More